AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7699834 — intervention group
Group type: EXPERIMENTAL
Intervention: SY5555 at a dose of 10 mg/kg
Number of subjects: 16
Study 7699834 — intervention group
Group type: EXPERIMENTAL
Intervention: SY5555 at a dose of 10 mg/kg (infants)
Number of subjects: 16
Study 7699834 — intervention group
Group type: COMPARATOR
Intervention: SY5555 (comparison with other antibiotics)
Number of subjects: 16
Study 2705661 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy with birch pollen allergen preparations, n = 42
Number of subjects: 72
Study 2705661 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral immunotherapy with birch pollen allergen preparations, n = 14
Number of subjects: 72
Study 2705661 — intervention group
Group type: COMPARATOR
Intervention: Placebo oral immunotherapy, n = 16
Number of subjects: 72
Study 1257366 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis cigarettes delivering 7 mg delta9-THC; administered during four training sessions and tested in the drug condition.
Number of subjects: 0
Study 1257366 — intervention group
Group type: COMPARATOR
Intervention: Non-drug condition; subjects trained without cannabis.
Number of subjects: 0
Study 31976814 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (2.5-10 mg/day)
Number of subjects: 60
Study 31976814 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ) (12.5-25 mg/day)
Number of subjects: 60
Study 30659611 — intervention group
Group type: EXPERIMENTAL
Intervention: INP104 1.45 mg
Number of subjects: 38
Study 30659611 — intervention group
Group type: COMPARATOR
Intervention: IV DHE 1.0 mg
Number of subjects: 38
Study 30659611 — intervention group
Group type: COMPARATOR
Intervention: Migranal 2.0 mg
Number of subjects: 38
Study 30659611 — intervention group
Group type: EXPERIMENTAL
Intervention: INP104
Number of subjects: 38
Study 30659611 — intervention group
Group type: COMPARATOR
Intervention: IV DHE
Number of subjects: 38
Study 30659611 — intervention group
Group type: COMPARATOR
Intervention: Migranal
Number of subjects: 38
Study 26095948 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine (titrated over 1-7 weeks to optimal dose ≤8 mg/24 h for patients not receiving levodopa, ≤16 mg/24 h for patients receiving levodopa)
Number of subjects: 349
Study 26095948 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 349
Study 26095948 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine
Number of subjects: 349
Study 23615091 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory naming
Number of subjects: 28
Study 23615091 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual naming
Number of subjects: 28
Study 23615091 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentence completion
Number of subjects: 28
Study 23615091 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual and auditory naming
Number of subjects: 28
Study 20798922 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypropylene mesh
Number of subjects: 100
Study 20798922 — intervention group
Group type: COMPARATOR
Intervention: Cadaveric fascia lata
Number of subjects: 100
Study 18060659 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight reduction (per 1 kg/year) in IFG individuals
Number of subjects: 1818
Study 18060659 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased triacylglycerol (per 1 mmol l(‐1) year(‐1)) in IFG individuals
Number of subjects: 1818
Study 18060659 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight reduction (per 1 kg/year) in IGT individuals
Number of subjects: 1818
Study 18060659 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline glucose measures in IFG individuals
Number of subjects: 1818
Study 18060659 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI (per kg/m2) in IFG individuals
Number of subjects: 1818
Study 18060659 — intervention group
Group type: EXPERIMENTAL
Intervention: Known hypertension in IGT individuals
Number of subjects: 1818
Study 18060659 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression rates from IFG to diabetes
Number of subjects: 1818
Study 18060659 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression rates from IGT to diabetes
Number of subjects: 1818
Study 16084584 — intervention group
Group type: EXPERIMENTAL
Intervention: Flowable compomer
Number of subjects: 30
Study 16084584 — intervention group
Group type: EXPERIMENTAL
Intervention: Flowable composite
Number of subjects: 30
Study 16084584 — intervention group
Group type: COMPARATOR
Intervention: Compomer restoration
Number of subjects: 30
Study 16084584 — intervention group
Group type: COMPARATOR
Intervention: Composite E
Number of subjects: 30
Study 16084584 — intervention group
Group type: COMPARATOR
Intervention: Composite RF
Number of subjects: 30
Study 12887362 — intervention group
Group type: EXPERIMENTAL
Intervention: Device group (device plus pamphlet)
Number of subjects: 46
Study 12887362 — intervention group
Group type: COMPARATOR
Intervention: Control group (pamphlet only)
Number of subjects: 46
Study 10850898 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy (30-minute massage with cocoa butter, twice a week for 5 weeks)
Number of subjects: 20
Study 10850898 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment control
Number of subjects: 20
Study 8612828 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted analysis
Number of subjects: 24
Study 8612828 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained andrologists
Number of subjects: 24
Study 8612828 — intervention group
Group type: EXPERIMENTAL
Intervention: Updated software for computer analysis
Number of subjects: 24
Study 1385972 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate
Number of subjects: 12
Study 1385972 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil
Number of subjects: 12
Study 1385972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6149965 — intervention group
Group type: EXPERIMENTAL
Intervention: BW 825C (4 mg)
Number of subjects: 20
Study 6149965 — intervention group
Group type: EXPERIMENTAL
Intervention: BW 825C (8 mg)
Number of subjects: 20
Study 6149965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30738171 — intervention group
Group type: EXPERIMENTAL
Intervention: GBR 830 (10 mg/kg intravenous on day 1 and day 29)
Number of subjects: 62
Study 30738171 — intervention group
Group type: EXPERIMENTAL
Intervention: GBR 830
Number of subjects: 62
Study 30738171 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 30578205 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile game group (n=36)
Number of subjects: 76
Study 30578205 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=40)
Number of subjects: 76
Study 27026087 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS) applied in the cervicothoracic region for 30 days.
Number of subjects: 56
Study 27026087 — intervention group
Group type: COMPARATOR
Intervention: Sham group (no stimulation).
Number of subjects: 56
Study 24479760 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi-based exercise program via telerehabilitation (45-minute session twice a week for eight consecutive weeks)
Number of subjects: 0
Study 24479760 — intervention group
Group type: COMPARATOR
Intervention: Tai Chi-based exercise program provided in person at home (45-minute session twice a week for eight consecutive weeks)
Number of subjects: 0
Study 24479760 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi-based exercise program via telerehabilitation
Number of subjects: 0
Study 24479760 — intervention group
Group type: COMPARATOR
Intervention: Tai Chi-based exercise program provided in person at home
Number of subjects: 0
Study 22403695 — intervention group
Group type: EXPERIMENTAL
Intervention: YouRAction
Number of subjects: 0
Study 22403695 — intervention group
Group type: EXPERIMENTAL
Intervention: YouRAction+e
Number of subjects: 0
Study 22403695 — intervention group
Group type: COMPARATOR
Intervention: Generic Information (GI)
Number of subjects: 0
Study 21143077 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaling hot dry air in a sauna
Number of subjects: 157
Study 21143077 — intervention group
Group type: COMPARATOR
Intervention: Dry air at room temperature in a sauna
Number of subjects: 157
Study 17545089 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone plus Ginkgo biloba leaf extract
Number of subjects: 35
Study 17545089 — intervention group
Group type: COMPARATOR
Intervention: Prednisone plus dipyridamole
Number of subjects: 35
Study 15932638 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-insulin-potassium infusion (GIK)
Number of subjects: 940
Study 15932638 — intervention group
Group type: COMPARATOR
Intervention: Control (no infusion)
Number of subjects: 940
Study 12498758 — intervention group
Group type: EXPERIMENTAL
Intervention: Scan-specific calculated attenuation correction (CAC)
Number of subjects: 0
Study 12498758 — intervention group
Group type: COMPARATOR
Intervention: Default measured attenuation correction (MAC)
Number of subjects: 0
Study 9653487 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 8573430 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiludronate therapy for 3 years
Number of subjects: 0
Study 8573430 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiludronate therapy for 2 years (non-fracture studies)
Number of subjects: 0
Study 2092187 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide (400 mg/die, 2 suppositories per day)
Number of subjects: 40
Study 2092187 — intervention group
Group type: COMPARATOR
Intervention: Flurbiprofen (200 mg/die, 2 suppositories per day)
Number of subjects: 40
Study 392743 — intervention group
Group type: EXPERIMENTAL
Intervention: Myc 2095 (20 mg)
Number of subjects: 40
Study 392743 — intervention group
Group type: EXPERIMENTAL
Intervention: triamcinolone hexacetonide (20 mg)
Number of subjects: 40
Study 392743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31903712 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (EXE) once weekly (2 mg/wk subcutaneously)
Number of subjects: 32
Study 31119179 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic Walking (NW) training for 10 weeks, 3 times a week
Number of subjects: 22
Study 31119179 — intervention group
Group type: COMPARATOR
Intervention: Control group with no specific intervention
Number of subjects: 22
Study 29256337 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week self-management intervention consisting of group meetings, individual counseling, and a book
Number of subjects: 64
Study 29256337 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving information about active lifestyle through one group meeting and a book
Number of subjects: 64
Study 25179153 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 µg nitroglycerin
Number of subjects: 1706
Study 25179153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1706
Study 23932910 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit Association Test (IAT)
Number of subjects: 73
Study 23932910 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report measures
Number of subjects: 73
Study 22545357 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger
Number of subjects: 0
Study 22545357 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 0
Study 22545357 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19860883 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 ml of triamcinolonacetonide (TCA)
Number of subjects: 21
Study 19860883 — intervention group
Group type: COMPARATOR
Intervention: NaCl 0.9% (placebo)
Number of subjects: 21
Study 17090280 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-caliber upper endoscope (9.2 mm)
Number of subjects: 244
Study 14975474 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined vitamin E (800 IU per day) and C (1000 mg per day)
Number of subjects: 30
Study 14975474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 14975474 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined vitamin E and C
Number of subjects: 30
Study 11329998 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental health treatment
Number of subjects: 1920
Study 11329998 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance abuse treatment
Number of subjects: 1920
Study 11329998 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for anxiety and depression
Number of subjects: 1920
Study 11329998 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance abuse symptoms
Number of subjects: 1920
Study 9221995 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin and aspirin
Number of subjects: 191
Study 9221995 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 191
Study 8073693 — intervention group
Group type: EXPERIMENTAL
Intervention: M‐1 daily in a dose of 15‐50 g, fish oil in a dose of 10‐30 ml
Number of subjects: 142
Study 8073693 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (no diet)
Number of subjects: 142
Study 3103989 — intervention group
Group type: EXPERIMENTAL
Intervention: Metered Dose Inhaler (MDI)
Number of subjects: 34
Study 3103989 — intervention group
Group type: COMPARATOR
Intervention: Up‐draft Nebulization (UDN)
Number of subjects: 34
Study 3103989 — intervention group
Group type: COMPARATOR
Intervention: Both MDI and UDN
Number of subjects: 34
Study 3103989 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine use of MDI
Number of subjects: 34
Study 31948641 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 18924
Study 31948641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18924
Study 29303469 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transforaminal endoscopic discectomy (PTED)
Number of subjects: 153
Study 29303469 — intervention group
Group type: COMPARATOR
Intervention: Microendoscopic discectomy (MED)
Number of subjects: 153
Study 29303469 — intervention group
Group type: EXPERIMENTAL
Intervention: PTED
Number of subjects: 153
Study 29303469 — intervention group
Group type: COMPARATOR
Intervention: MED
Number of subjects: 153
Study 28858279 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthodontic treatment with bracket-systems and dental foam (Splat, Russia) after meal (Group 3)
Number of subjects: 106
Study 28858279 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthodontic treatment with bracket-systems (Group 2)
Number of subjects: 106
Study 28858279 — intervention group
Group type: COMPARATOR
Intervention: Control group with no orthodontic treatment (n=35)
Number of subjects: 106
Study 24077380 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching condition (SC)
Number of subjects: 15
Study 24077380 — intervention group
Group type: COMPARATOR
Intervention: Control condition (CC)
Number of subjects: 15
Study 23021093 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 234
Study 20725117 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (25 g.day(‐1) for 5 days, followed by 5 g.day(‐1) for 3 days)
Number of subjects: 40
Study 18670219 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (400 mg daily for 3 days)
Number of subjects: 208
Study 18670219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study 15957564 — intervention group
Group type: EXPERIMENTAL
Intervention: Assigned a roommate who binge drank in high school
Number of subjects: 714
Study 15957564 — intervention group
Group type: COMPARATOR
Intervention: Assigned a nonbinge-drinking roommate
Number of subjects: 714
Study 15957564 — intervention group
Group type: EXPERIMENTAL
Intervention: Students who did not engage in these behaviors in high school
Number of subjects: 714
Study 12618570 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental arm receiving a workbook and a series of six 4-page newsletters delivered every 7 weeks, tailored to individual characteristics
Number of subjects: 530
Study 12618570 — intervention group
Group type: COMPARATOR
Intervention: Control arm receiving a series of nontailored health brochures
Number of subjects: 530
Study 10498145 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 0
Study 10498145 — intervention group
Group type: COMPARATOR
Intervention: Control (no abciximab)
Number of subjects: 0
Study 7861015 — intervention group
Group type: EXPERIMENTAL
Intervention: Stavudine (daily doses ranging from 0.1 to 12.0 mg/kg)
Number of subjects: 259
Study 7861015 — intervention group
Group type: EXPERIMENTAL
Intervention: Stavudine (doses of < or = 2 mg/kg/day, n = 216)
Number of subjects: 259
Study 7861015 — intervention group
Group type: EXPERIMENTAL
Intervention: Stavudine
Number of subjects: 259
Study 1952200 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (0.5 MAC inspired concentration)
Number of subjects: 40
Study 1952200 — intervention group
Group type: COMPARATOR
Intervention: Halothane (0.5 MAC inspired concentration)
Number of subjects: 40
Study 6894241 — intervention group
Group type: EXPERIMENTAL
Intervention: 375 mg azidocillin tablets
Number of subjects: 0
Study 6894241 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg azidocillin tablets
Number of subjects: 0
Study 6894241 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 mg azidocillin tablets
Number of subjects: 0
Study 6894241 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg azidocillin suspension
Number of subjects: 0
Study 6894241 — intervention group
Group type: EXPERIMENTAL
Intervention: 799 mg azidocillin i.m. injection
Number of subjects: 0
Study 6894241 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg azidocillin tablets twice daily for 14 days
Number of subjects: 0
Study 6894241 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg azidocillin i.v. dosage
Number of subjects: 0
Study 6894241 — intervention group
Group type: EXPERIMENTAL
Intervention: i.m. azidocillin dose
Number of subjects: 0
Study 6894241 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. azidocillin doses
Number of subjects: 0
Study 6894241 — intervention group
Group type: EXPERIMENTAL
Intervention: other dosage forms of azidocillin
Number of subjects: 0
Study 6894241 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. administration of azidocillin
Number of subjects: 0
Study 31314208 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational strategy (I prefer plain water)
Number of subjects: 777
Study 31314208 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 777
Study 28811737 — intervention group
Group type: EXPERIMENTAL
Intervention: Faith-based intervention
Number of subjects: 469
Study 28811737 — intervention group
Group type: EXPERIMENTAL
Intervention: Secular intervention
Number of subjects: 469
Study 28811737 — intervention group
Group type: COMPARATOR
Intervention: Self-guided control group
Number of subjects: 469
Study 28811737 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer-assessed daily steps
Number of subjects: 469
Study 28811737 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometer-assessed minutes of daily moderate-to-vigorous PA
Number of subjects: 469
Study 28811737 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported minutes of weekly walking and moderate- and vigorous-intensity PA
Number of subjects: 469
Study 25782408 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic clopidogrel besylate (CB)
Number of subjects: 1800
Study 25782408 — intervention group
Group type: COMPARATOR
Intervention: Innovator clopidogrel hydrogen sulphate (CHS)
Number of subjects: 1800
Study 23696818 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratio measure of health inequality
Number of subjects: 40
Study 23696818 — intervention group
Group type: COMPARATOR
Intervention: Difference measure of health inequality
Number of subjects: 40
Study 21211558 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitter melon 2,000 mg/day
Number of subjects: 0
Study 21211558 — intervention group
Group type: COMPARATOR
Intervention: Metformin 1,000 mg/day
Number of subjects: 0
Study 21211558 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitter melon 500 mg/day
Number of subjects: 0
Study 21211558 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitter melon 1,000 mg/day
Number of subjects: 0
Study 18437414 — intervention group
Group type: EXPERIMENTAL
Intervention: One-back choice RT task
Number of subjects: 0
Study 18437414 — intervention group
Group type: EXPERIMENTAL
Intervention: Response-stimulus interval of the one-back task
Number of subjects: 0
Study 16842799 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens 0.625 mg (CEE)
Number of subjects: 88
Study 16842799 — intervention group
Group type: EXPERIMENTAL
Intervention: 17beta-estradiol 1mg plus norethisterone acetate 0.5mg (E(2)/NETA)
Number of subjects: 88
Study 16842799 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene HCl 60 mg
Number of subjects: 88
Study 16842799 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 88
Study 15285981 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased awareness of psychiatric condition at baseline
Number of subjects: 980
Study 15285981 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in awareness associated with treatment
Number of subjects: 980
Study 11300390 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine (50 microg kg(-1)) and glycopyrrolate (10 microg kg(-1))
Number of subjects: 90
Study 11300390 — intervention group
Group type: COMPARATOR
Intervention: NaCl i.v. as placebo
Number of subjects: 90
Study 11300390 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 90
Study 9397292 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS 30-120 mg/day
Number of subjects: 46
Study 9397292 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 5-30 mg/day
Number of subjects: 46
Study 7949259 — intervention group
Group type: COMPARATOR
Intervention: CA 19-9
Number of subjects: 171
Study 7949259 — intervention group
Group type: COMPARATOR
Intervention: CA 50
Number of subjects: 171
Study 2905724 — intervention group
Group type: EXPERIMENTAL
Intervention: Temocillin
Number of subjects: 308
Study 2905724 — intervention group
Group type: COMPARATOR
Intervention: Control (no antibiotic cover)
Number of subjects: 308
Study 30010353 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension Tamer (TT) guided BAM sessions for 5-min intervals twice daily
Number of subjects: 64
Study 30010353 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension Tamer (TT) guided BAM sessions for 10-min intervals twice daily
Number of subjects: 64